Related references
Note: Only part of the references are listed.Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia
Yuichi Ishikawa et al.
LEUKEMIA RESEARCH (2011)
Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms
Francesca Florio et al.
HUMAN MOLECULAR GENETICS (2010)
High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse
Weiying Gu et al.
LEUKEMIA RESEARCH (2010)
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study
A. M. Willasch et al.
LEUKEMIA (2009)
The ratio of ±KTS splice variants of the Wilms' tumour suppressor protein WT1 mRNA is determined by an intronic enhancer
Cheng Yang et al.
BIOCHEMISTRY AND CELL BIOLOGY (2008)
Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
Priya Virappane et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase
Gunter Kerst et al.
LEUKEMIA RESEARCH (2008)
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia
Patricia C. Rodrigues et al.
PEDIATRIC BLOOD & CANCER (2007)
Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells
E. A. Burwell et al.
ONCOGENE (2007)
The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells
Youqi Han et al.
BREAST CANCER RESEARCH (2007)
Different isoforms of the Wilms' tumour protein WT1 have distinct patterns of distribution and trafficking within the nucleus
J. R. Dutton et al.
CELL PROLIFERATION (2006)
The many facets of the Wilms' tumour gene, WT1
Peter Hohenstein et al.
HUMAN MOLECULAR GENETICS (2006)
The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain
A. A. Morrison et al.
BIOCHEMISTRY AND CELL BIOLOGY (2006)
N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia
Anwar Hossain et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway
K. Ito et al.
ONCOGENE (2006)
The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron
Yeou-cherng Bor et al.
GENES & DEVELOPMENT (2006)
High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia
H Lapillonne et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
T Jomgeow et al.
CANCER SCIENCE (2006)
Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring
L Boublikova et al.
LEUKEMIA (2006)
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
M Weisser et al.
LEUKEMIA (2005)
The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes
M Niksic et al.
HUMAN MOLECULAR GENETICS (2004)
Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours
AR Dallosso et al.
HUMAN MOLECULAR GENETICS (2004)
Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants
JM Siehl et al.
ANNALS OF HEMATOLOGY (2004)
WT1 gene expression:: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients -: results from a single-centre study
M Ostergaard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome
D Cilloni et al.
ACTA HAEMATOLOGICA (2004)
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
E Beillard et al.
LEUKEMIA (2003)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Analytical validation of a real-time reverse transcription-polymerase chain reaction quantitation of different transcripts of the Wilms' tumor suppressor gene (WT1)
CI Dumur et al.
ANALYTICAL BIOCHEMISTRY (2002)
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
D Cilloni et al.
LEUKEMIA (2002)
Real-time quantitative PCR detection of WT1 gene expression in children with AML:: prognostic significance, correlation with disease status and residual disease detection by flow cytometry
J Trka et al.
LEUKEMIA (2002)
WT1 proteins: functions in growth and differentiation
V Scharnhorst et al.
GENE (2001)
Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA:: implications for monitoring human leukaemias
KA Kreuzer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells
LW Ellisen et al.
EMBO JOURNAL (2001)
Wilms' tumor gene WT1:: Its oncogenic function and clinical application
H Sugiyama
INTERNATIONAL JOURNAL OF HEMATOLOGY (2001)